According to a report from the National Eye Institute and Prevent Blindness America, the prevalence of open-angle glaucoma (OAG) has increased in the United States by more than 20 percent. More than 2.7 million Americans over 40 have OAG. There are various risk factors for glaucoma, such as age and race, but it can still be prevented. By scheduling a visit with an ophthalmologist, people can reduce their chances of developing the world’s second leading cause of blindness with early treatment (one example).
As January is Glaucoma Awareness Month, share this statistic with friends and family, and encourage them to schedule an eye exam as soon as possible.
Source: Monthly Prescribing Reference
Posted in Aging, Eye Drops, Open Angle Glaucoma, prevention, publicity, Research
Tagged americans, angle, awareness, eye, factors, glaucoma, increasing, institute, january, national, nei, oag, open, ophthalmologist, rates, report, risk, states, treatment, united
13 February 2012: The FDA approved a new treatment for open-angle glaucoma, which is the most common form of the eye disease. It is called Zioptan, and is made by Merck. Like other medications described in other posts, its active ingredient is tafluprost. Zioptan is special because it does not use preservatives in the solution. Most other glaucoma drugs use preservatives, which can cause negative reactions in patients. However, there are, of course, adverse side effects that can occur in patients taking Zioptan. The most common side effect is conjunctival hyperemia, also known as “red eye”. Merck also “advises that patients with active intraocular inflammation, aphakic patients, and pseudophakic patients with torn posterior lens capsule, or others at risk for macular edema, should be cautious about using the drug.”
Posted in Eye Drops, Overview, Symptoms, treatment
Tagged alternative, c25h34f2o5, drug, medication, merck, new, preservatives, solution, tafluprost, treatment, xalatan, zioptan
A new kind of glaucoma drop, called Tafluprost is currently being investigated. Like most glaucoma drops, it is to be used once a day, and it has the same effect as other twice-a-day glaucoma drops. Another benefit of Tafluprost is that it does not contain benzalkonium chloride, a preservative often used in other glaucoma drops, which can cause allergic reactions in patients. The study, sponsored by Merck, had 643 patients participating over twelve weeks. Intraocular pressure (IOP) was recorded to have fallen approximately 6.2 to 7.4 mm Hg with tafluprost after three checks, while Timolol, another more common drug used for glaucoma only reduces IOP 5.7 to 7.5 mm Hg. This is a major breakthrough, and hopefully the FDA will approve it for use.
Posted in clinical trial, Eye Drops, Overview, Research, Studies, treatment
Tagged benzalkonium, chloride, drop, effect, free, merck, once, patients, preservative, study, tafluprost, treatment, trial, twice
It’s finally here. A generic prescription medication for glaucoma. For years, glaucoma patients have had to shell out for expensive glaucoma medications such as Xalatan, Lumigan, and Travatan. Finally, Bausch and Lomb, partnered with pharmaceutical generic giant Mylan has created Latonoprost, a generic glaucoma eye drop. The price with medical insurance is significantly less, and can save patients as much as forty to fifty USD.
You can read the press release from Mylan here.
Posted in Eye Drops, Symptoms, treatment
Tagged bausch, cheap, drops, eye, generic, isotonic, lomb, lumigan, mylan, prescription, save, travatan, treatment, xalatan